Episode 274: ESMO 2023: STEAP1/BiTE in CRPC Shows Promise

Kevin Kelly, DO, discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for hormone-refractive prostate cancer.
Dr. Kelly serves as Chair of the Department of Medical Oncology and Director of the Division of Solid Tumor Oncology at Thomas Jefferson University in Philadelpha, PA.